Edwards Lifesciences exec exercises, sells 1,019 shares
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share and immediately sold 1,019 shares at a weighted average price of $80.9840 per share.
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share and immediately sold 1,019 shares at a weighted average price of $80.9840 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025, indicating they were scheduled in advance. Following the transactions, Lippis directly owns 33,933.9103 shares of Edwards Lifesciences common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,019 shares ($22K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Lippis Daniel J.
Role
CVP, TAVR
Sold
1,019 shs ($83K)
Approx. gross sale proceeds
$83K
Approx. exercise cost
$60K
Approx. pre-tax spread
$22K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 1,019 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,019 | $59.2567 | $60K |
| Sale | Common Stock | 1,019 | $80.984 | $83K |
Holdings After Transaction:
Employee Stock Option (Right to Acquire) — 2,038 contracts (Direct);
Common Stock — 33,933.9103 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $80.64 to $81.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 1,019 shares
Exercise price: $59.2567 per share
Shares sold: 1,019 shares
+3 more
6 metrics
Options exercised
1,019 shares
Employee Stock Option exercise on April 6, 2026
Exercise price
$59.2567 per share
Employee Stock Option on Edwards Lifesciences common stock
Shares sold
1,019 shares
Open-market sale on April 6, 2026
Weighted average sale price
$80.9840 per share
Sale of 1,019 common shares, trade range $80.64–$81.07
Shares owned after transactions
33,933.9103 shares
Direct common stock holdings following April 6, 2026 trades
Option expiration date
May 7, 2026
Expiration of Employee Stock Option that was exercised
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option, open-market sale, weighted average sale price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option financial
"security_title: Employee Stock Option (Right to Acquire)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Form 4 regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What did Edwards Lifesciences (EW) executive Daniel J. Lippis do in this Form 4 filing?
Daniel J. Lippis exercised employee stock options for 1,019 Edwards Lifesciences shares and sold 1,019 shares in the open market. The exercise converted options into common stock, and the sale realized cash while leaving him with a remaining direct holding of 33,933.9103 shares.
Were Daniel J. Lippis’s Edwards Lifesciences (EW) trades pre-planned under Rule 10b5-1?
Yes. The filing states the reported transactions were effected under a Rule 10b5-1 trading plan adopted on July 30, 2025. Such plans schedule trades in advance, indicating these option exercises and share sales followed a predetermined program rather than discretionary, real-time decisions.
What type of securities did Daniel J. Lippis exercise in this Edwards Lifesciences (EW) Form 4?
Lippis exercised an Employee Stock Option covering 1,019 shares of Edwards Lifesciences common stock. The option had an exercise price of $59.2567 per share, with an original exercise date of May 8, 2020 and an expiration date of May 7, 2026, as disclosed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
